Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Mar
19
Today In Oncology
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria
PSMA PET-CT Scan Reduces Need for Prostate Cancer Biopsies
New AACR President-Elect and Board Members Announced
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer (1)
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo